Fortescue Expands Copper Portfolio With Full Takeover of Alta Copper 
Amazon in Talks to Invest $10 Billion in OpenAI as AI Firm Eyes $1 Trillion IPO Valuation 
Korea Zinc to Build $7.4 Billion Critical Minerals Refinery in Tennessee With U.S. Government Backing 
Korea Zinc Plans $6.78 Billion U.S. Smelter Investment With Government Partnership 
Trump Sues BBC for Defamation Over Edited Capitol Riot Speech Clip 
SpaceX Begins IPO Preparations as Wall Street Banks Line Up for Advisory Roles 
EU Signals Major Shift on 2035 Combustion Engine Ban Amid Auto Industry Pressure 
Sanofi’s Efdoralprin Alfa Gains EMA Orphan Status for Rare Lung Disease 
Apple Explores India for iPhone Chip Assembly as Manufacturing Push Accelerates 
Nvidia Weighs Expanding H200 AI Chip Production as China Demand Surges 
Ford Takes $19.5 Billion Charge as EV Strategy Shifts Toward Hybrids 
Robinhood Expands Sports Event Contracts With Player Performance Wagers 
Woolworths Faces Fresh Class Action Over Alleged Underpayments, Shares Slide 
Blackstone Leads $400 Million Funding Round in Cyera at $9 Billion Valuation 
FDA Says No Black Box Warning Planned for COVID-19 Vaccines Despite Safety Debate 
Biren Technology Targets Hong Kong IPO to Raise $300 Million Amid China’s AI Chip Push 
Nomura Expands Alternative Assets Strategy With Focus on Private Debt Acquisitions 
WILMINGTON, Del., Jan. 15, 2016 (GLOBE NEWSWIRE) -- Rigrodsky & Long, P.A.:
- Do you, or did you, own shares of XBiotech Inc. (NASDAQ:XBIT)?
- Did you purchase your shares pursuant and/or traceable to the April 15, 2015 initial public offering, or between April 15, 2015 and November 23, 2015, inclusive?
- Did you lose money in your investment?
Rigrodsky & Long, P.A. reminds shareholders of XBiotech Inc. (“XBiotech” or the “Company”) (NASDAQ:XBIT) of an upcoming deadline involving a securities fraud class action lawsuit commenced against the Company. A complaint was filed in the United States District Court for the Western District of Texas on behalf of all persons or entities that purchased the common stock of XBiotech between April 15, 2015 and November 23, 2015, inclusive (the “Class Period”) alleging violations of the Securities Exchange Act of 1934 against the Company and certain of its officers. A separate complaint has been filed in the Superior Court of the State of California on behalf of all persons or entities that acquired XBiotech shares pursuant or traceable to its initial public offering (“IPO”) commenced on or about April 15, 2015, alleging violations of the Securities Exchange Act of 1933 against the Company and certain of its officers.
If you wish to serve as lead plaintiff, you must move the Court no later than February 1, 2016. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. Any member of the proposed class may move the court to serve as lead plaintiff through counsel of their choice, or may choose to do nothing and remain an absent class member.
If you purchased shares of XBiotech in the April 15, 2015 offering, or during the period April 15, 2015 and November 23, 2015, inclusive, and wish to discuss this action or have any questions concerning this notice or your rights or interests, please contact Timothy J. MacFall, Esquire or Peter Allocco of Rigrodsky & Long, P.A., 2 Righter Parkway, Suite 120, Wilmington, DE 19803 at (888) 969-4242; by e-mail to [email protected]; or at: http://rigrodskylong.com/investigations/xbiotech-inc-xbit.
Attorney advertising. Prior results do not guarantee a similar outcome.
CONTACT: Rigrodsky & Long, P.A. Timothy J. MacFall, Esquire Peter Allocco (888) 969-4242 (516) 683-3516 Fax: (302) 654-7530 [email protected] http://www.rigrodskylong.com
